TY - JOUR
T1 - Sensor-augmented pump therapy in very young children with type 1 diabetes
T2 - An efficacy and feasibility observational study
AU - Frontino, Giulio
AU - Bonfanti, Riccardo
AU - Scaramuzza, Andrea
AU - Rabbone, Ivana
AU - Meschi, Franco
AU - Rigamonti, Andrea
AU - Battaglino, Roseila
AU - Favalli, Valeria
AU - Bonura, Clara
AU - Sicignano, Sabrina
AU - Gioia, Elisa
AU - Zuccotti, Gian Vincenzo
AU - Cerutti, Franco
AU - Chiumello, Giuseppe
PY - 2012/9/1
Y1 - 2012/9/1
N2 - Background: Efficacy and feasibility of sensor-augmented pump (SAP) therapy were evaluated in very young children with type 1 diabetes (T1D). Subjects and Methods: SAP (Dexcom [San Diego, CA] Seven Plus™ usage combined with insulin pump) therapy was retrospectively evaluated in 28 children (15 boys) younger than 7 years (mean age, 5.8±1.2 years; range, 3-7 years), with T1D. Glycosylated hemoglobin (HbA1c) was evaluated at baseline and at the end of the study, as were efficacy and feasibility of the system, using a rating scale (with 3 being the most positive). Results: SAP has been used for at least 6 months by 85% of patients, with an overall good satisfaction (92%). The greatest perceived benefit was the reduced fear of hypoglycemia (score of 3, 81%). HbA1c significantly improved only in patients with baseline HbA1c >7.5% (P=0.026). Conclusions: SAP therapy is effective and feasible in preschool children with T1D. In patients with high HbA1c at baseline it provide a 0.9% decrease, sustained for at least 6 months.
AB - Background: Efficacy and feasibility of sensor-augmented pump (SAP) therapy were evaluated in very young children with type 1 diabetes (T1D). Subjects and Methods: SAP (Dexcom [San Diego, CA] Seven Plus™ usage combined with insulin pump) therapy was retrospectively evaluated in 28 children (15 boys) younger than 7 years (mean age, 5.8±1.2 years; range, 3-7 years), with T1D. Glycosylated hemoglobin (HbA1c) was evaluated at baseline and at the end of the study, as were efficacy and feasibility of the system, using a rating scale (with 3 being the most positive). Results: SAP has been used for at least 6 months by 85% of patients, with an overall good satisfaction (92%). The greatest perceived benefit was the reduced fear of hypoglycemia (score of 3, 81%). HbA1c significantly improved only in patients with baseline HbA1c >7.5% (P=0.026). Conclusions: SAP therapy is effective and feasible in preschool children with T1D. In patients with high HbA1c at baseline it provide a 0.9% decrease, sustained for at least 6 months.
UR - http://www.scopus.com/inward/record.url?scp=84865778366&partnerID=8YFLogxK
U2 - 10.1089/dia.2012.0044
DO - 10.1089/dia.2012.0044
M3 - Article
SN - 1520-9156
VL - 14
SP - 762
EP - 764
JO - Diabetes Technology and Therapeutics
JF - Diabetes Technology and Therapeutics
IS - 9
ER -
